Phase II Trial of Regorafenib and Oral Methotrexate in Previously Treated Advanced KRAS-Mutant NSCLC.
Aredo JV, Wakelee HA, Ramchandran KJ, Neal JW, Diehn M, Hui AB, Salahudeen A, Kwong B, Berry GJ, Guo HH, Cunanan K, Vali S, Pancirer D, Tsang V, Hwang G, Loza M, Johnson B, Blanchard I, Padda SK.
Aredo JV, et al. Among authors: johnson b.
JTO Clin Res Rep. 2024 Oct 17;5(12):100741. doi: 10.1016/j.jtocrr.2024.100741. eCollection 2024 Dec.
JTO Clin Res Rep. 2024.
PMID: 39624248
Free PMC article.